Enara Bio's purpose is to shine a light on unconventional T cell targets to develop cancer immunotherapies designed to provide lasting benefit for broad patient populations. Our proprietary EDAPT platform enables us to discover a novel and differentiated class of cancer-specific targets from the genomic dark matter, which we call Dark Antigens. We are pioneering approaches to exploit these Dark Antigen targets with a range of immunotherapeutic modalities, including bispecific T-cell engagers, adoptive cell therapies and cancer vaccines.
Enara Bio was founded in 2016 and has been well funded to invest in the build out and growth of our R&D efforts and our fantastic team. The company is based in Oxford, UK.
MNCJobs.co.uk will not be responsible for any payment made to a third-party. All Terms of Use are applicable.